NCT06993233View on ClinicalTrials.gov

A Study With CIT-013 in HS Patients

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

96

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

July 31, 2027

Conditions

Hidradenitis Suppurativa (HS)

Interventions

DRUG

CIT-013 high dose

subcutaneous injection

DRUG

CIT-013 medium dose

subcutaneous injection

DRUG

Placebo

subcutaneous injection

Trial Locations (1)

Unknown

Erasmus UMC, Rotterdam

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Citryll BV

INDUSTRY

NCT06993233 - A Study With CIT-013 in HS Patients | Biotech Hunter | Biotech Hunter